Artefactual 25-OH vitamin D concentration in multiple myeloma

Author(s):  
Michal WS Ong ◽  
Rashim Salota ◽  
Tracy Reeman ◽  
Marta Lapsley ◽  
Lydia Jones

The most commonly used techniques to measure vitamin D are automated immunoassays which are known to be affected by interferences, especially from immunoglobulins present in the patient’s serum. We present a case of a patient with myeloma in whom interference with the vitamin D assay was identified. An 83-year-old female, known to have IgG myeloma, was found to have a high concentration of 25-OH vitamin D on a routine test without any signs of vitamin D toxicity. She was not taking vitamin D supplements or any other multivitamin preparation and had minimal sun exposure. The initial and subsequent samples run by the ARCHITECT 25-OH vitamin D assay (chemiluminescent microparticle immunoassay technology, Abbott Laboratories, Abbott Park, IL) showed a high concentration of 25-OH vitamin D of 281 nmol/L and 327 nmol/L, respectively. Further fresh samples taken for 25-OH vitamin D and analysed by liquid chromatography-mass spectrometry (LC-MS/MS) and ARCHITECT analysis showed results of 49 nmol/L and 289 nmol/L, respectively. Our patient had high concentrations of circulating IgG paraproteins and had a long history of rheumatoid arthritis; paraproteins and rheumatoid factor may interfere in the assay. In conclusion, we report a case of a patient with IgG myeloma and rheumatoid arthritis with high concentrations of 25-OH vitamin D detected by the Abbott ARCHITECT, but not by a reference method (LC-MS/MS). The most likely cause of the discordant results is interference in the immunoassay by the paraprotein but interference from rheumatoid factor remains a possibility.

2020 ◽  
Vol 4 (Supplement_1) ◽  
Author(s):  
Shoshana Tell ◽  
Erin Finn ◽  
Rebecca Anne Ohman-Hanson ◽  
Nina Ma

Abstract Background: Mutations in CYP24A1, which encodes 24-hydroxylase, the key enzyme for Vitamin D breakdown, cause symptomatic hypercalcemia and nephrocalcinosis in infants on Vitamin D supplementation. New, symptomatic diagnoses of idiopathic infantile hypercalcemia without exogenous supplementation are rare. Previous case reports describe a seasonal effect with worsening hypercalcemia and hypercalciuria during summertime, attributed to increased sun exposure and endogenous Vitamin D production. Clinical Case: A 10-month-old female presented to endocrine care with hypercalcemia and nephrocalcinosis, detected on renal ultrasound (US) due to history of UTI. Her first renal US and serum calcium (Ca) at 3mo of age were normal. Subsequent renal US at 6mo and 9mo of age demonstrated nephrocalcinosis, prompting nephrology and endocrine evaluation. History was significant for failure to thrive. She was born in the fall, with worsening hypercalcemia and nephrocalcinosis during the summer. Diet consisted of standard infant formula and age appropriate solid foods with no added Vitamin D supplementation (~300 IU/day in her formula). She had no family history of nephrocalcinosis, nephrolithiasis, bone disease, or disorders of Ca regulation. Initial labs were notable for Ca corrected for albumin 11.5 (7.8-11.1 mg/dL), PTH <4 (8.7-77.1 pg/mL), 25-OH-Vitamin D 81 (30-96 ng/mL), 1,25-OH-Vitamin D 23.1 (26.1-95 pg/mL), Urine Ca/creatinine ratio of 0.9 mg/mg (<0.81), normal chromosomal microarray, and normal thyroid function tests. She was started on reduced mineral formula PM 60/40. One week later, repeat Ca level increased to Ca corrected 14.2 (7.8-11.1 mg/dL). She was admitted for IV fluids and pamidronate, and was transitioned to a low Ca and Vitamin D formula (Calcilo), with improvement in Ca levels. Testing revealed an increased ratio of 25-OH-Vitamin D to 24,25-OH-Vitamin D of 192 (normal <25), and genetic testing showed 2 pathogenic missense mutations in CYP24A1 genes: c.1226T>C p.(Leu409Ser) and c.1186C>T p.(Arg396Trp). The Leu409Ser mutation has shown a small amount of 24-hydroxylase activity in previous in vitro analysis. She has continued a low Ca diet with stable Ca corrected of 10.7-10.8 (8.7-9.8 mg/dL) and significantly improved weight gain. Conclusion: This is one of the few documented cases of symptomatic idiopathic infantile hypercalcemia secondary to CYP24A1 mutation in an infant without exogeneous Vitamin D supplementation. Her nephrocalcinosis and hypercalcemia worsened over the summer, suggesting increased sun exposure may have been a contributing factor. This case demonstrates that 1,25-OH-Vitamin D levels may be normal or low in this condition, particularly for individuals with the Leu409Ser mutation who may retain partial 24-hydroxylase function.


Author(s):  
ABDULNASSER M AL-GEBORI ◽  
MOHAMMED HADI MUNSHED ALOSAMI ◽  
NAWAL HAIDER AL-HASHIMI

Objectives: The objectives of the study were to evaluate changes in 25(OH) Vitamin D levels and some biochemical parameters in rheumatoid arthritis (RA) patients compared with healthy controls and assess the correlation of 25-hydroxy Vitamin D, calcium, magnesium, and disease activity. Study the effects of anti-RA drugs on these biochemical parameters and also the role of supplements calcium and 25-OH Vitamin D in RA patients. Methods: This study conducted between 60 patients for RA and 20 healthy controls according to the American College of Rheumatology standards in 2010. In this study, 25-hydroxy Vitamin D was measured using an enzyme-linked immunosorbent assay, and also some biochemical parameters were measured with a spectrophotometer (Humalyzer 2000). Results: Serum 25(OH) Vitamin D, calcium, magnesium, and albumin levels were significantly lower in RA patients compared with healthy controls. Serum alanine aminotransferase aspartate aminotransferase levels were significantly increased in RA patients compared with healthy controls. The correlation was non-significantly among 25-hydroxy Vitamin D and clinical disease activity index (CDAI), while the results showed significantly inverse correlation calcium and magnesium concentrations with CDAI. Conclusion: 25-OH Vitamin D, calcium, albumin, and magnesium deficiency appear to be widespread in patients with RA. Thus, biochemical changes in RA are reflected in the pathogenesis of RA. Furthermore, in these results, there is no relationship between Vitamin D and the disease activity, while there is a relationship between calcium and magnesium with disease activity.


BMJ ◽  
1980 ◽  
Vol 280 (6229) ◽  
pp. 1416-1416 ◽  
Author(s):  
H A Bird ◽  
M Peacock ◽  
J H Storer ◽  
V Wright

2009 ◽  
Vol 36 (5) ◽  
pp. 943-946 ◽  
Author(s):  
MARIE FESER ◽  
LEZLIE A. DERBER ◽  
KEVIN D. DEANE ◽  
DENNIS C. LEZOTTE ◽  
MICHAEL H. WEISMAN ◽  
...  

Objective.To evaluate the association between rheumatoid arthritis (RA)-related autoantibodies and plasma 25,OH vitamin D in subjects at risk for RA.Methods.In 1210 subjects without RA, 76 were positive for anti-cyclic citrullinated peptide antibodies or for at least 2 rheumatoid factors (RF; by nephelometry: RF-IgM, RF-IgG, RF-IgA). 25,OH vitamin D was measured in these cases and 154 autoantibody-negative controls from this cohort.Results.25,OH vitamin D levels did not differ between cases and controls (adjusted OR 1.23, 95% CI 0.93–1.63).Conclusion.Vitamin D concentrations are not associated with RA-related autoimmunity in unaffected subjects at increased risk for RA.


2008 ◽  
Vol 159 (5) ◽  
pp. 653-657 ◽  
Author(s):  
Manel Puig-Domingo ◽  
Gonzalo Díaz ◽  
Joanna Nicolau ◽  
Cristián Fernández ◽  
Sergio Rueda ◽  
...  

ObjectiveHypoparathyroidism is usually controlled with calcium and vitamin-D supplements; in very few cases this treatment fails and teriparatide may be an alternative. We report the first case of hypoparathyroidism refractory to vitamin-D therapy requiring multipulse teriparatide treatment.Case reportA 53 year-old woman presented severe hypocalcemia and hypomagnesemia after thyroidectomy. Preoperatively, mild hypercalciuria was detected with parathyroid hormone (PTH) 69 pg/ml (normal 10–45) and 25-OH-vitamin D 9 ng/ml (normal 20–40) and normal levels of magnesium. No response was seen with oral and i.v. calcium and magnesium, or even with 5 μg calcitriol/day, suggesting a vitamin-D resistance status. Calcium sensor and vitamin-D receptor gene mutation studies were negative.Interventions and resultsThe following treatments were tried: i) s.c. recombinant human PTH (rhPTH) 1–34 plus oral calcitriol, calcium, and magnesium, was partially effective, but symptoms resumed 4 h after the injection of 20 μg rhPTH; stable calcemia was not achieved even with 4–6 injections/day of teriparatide; ii) two trials of heterologous parathyroid transplant were performed but rejection was detected 3 months after; iii) i.v. magnesium decreased rhPTH requirements but i.m. administration was not tolerated and iv) multipulse s.c. infusion of teriparatide achieved complete normalization of serum calcium, phosphate, magnesium, calciuria and magnesuria with relatively low rhPTH doses (25–35 μg/day) for more than a year.ConclusionsVitamin-D unresponsiveness leads to uncontrolled hypocalcemia when postsurgical hypoparathyroidism occurs; in situations of no response to usual or higher doses of vitamin-D and s.c. injections of rhPTH, treatment with teriparatide multipulse s.c. infusor is an effective and safe alternative.


2021 ◽  
Vol 5 (Supplement_1) ◽  
Author(s):  
Qurat Ul Ain Amjad ◽  
Spencer Ellis

Abstract Case report - Introduction Rheumatoid arthritis (RA) is an autoimmune inflammatory arthropathy with systemic manifestations. It is 4-times more common in females. RA is recognised to induce bone loss and decrease in bone mineral density (BMD). Management may include corticosteroids (CS) for new presentations, acute flares, and more rarely longer-term management, which increases bone fragility. Patients are at 30—50% increased risk of developing osteoporosis with a 30% increase in fracture risk. This risk rises with the level of persistent disease inflammation. We present a case of a lady with longstanding RA, who sustained multiple bone fractures without significant osteoporosis on bone density scanning. Case report - Case description Our patient is a 64-year-old headteacher who took early retirement due to reduced mobility after 20 years of seropositive RA. She had received multiple disease modifying drugs (DMARDs) and biologics therapies, requiring repeated alterations primarily due to treatment failure. She was commenced on alendronic acid due to osteopaenia of the hip but 2 years later sustained a fractured neck of femur and was switched to risedronate. A year later she presented with acutely painful and swollen right foot and ankle without history of trauma. X-rays showed progressive degenerative change whilst inflammatory markers were normal. Ultrasound demonstrated sub-clinical synovitis. Her medication was optimised but the ankle swelling persisted, rendering her wheelchair-reliant. MRI revealed multiple stress fractures involving calcaneum, talus and 5th proximal phalanx. She was treated with 16 weeks of an Aircast boot. An old right upper medial tibial fracture was also identified. Repeat dual energy X-ray absorptiometry (DEXA) scan showed osteopaenia but with improvement from the previous scan (T score of -2.1 total hip and -1.6 lumbar vertebra). She smoked 1 cigarette a day, did not drink alcohol and there was no parental history of fractures. No evidence of malabsorption or endocrine disorder was identified. Unusually, she had received tamoxifen in her late 20s for cancer prevention based on breast fibroadenosis and she experienced early menopause aged 36 years. Inflammatory markers, calcium, parathyroid hormone, and immunoglobulins were normal. Vitamin D3 levels were insufficient at 40.3 nmol/l and replacement was initiated, following which she was switched to intravenous zoledronic acid. After one infusion of zolendronate, she twisted her right ankle and sustained a new malleolar fracture. She was converted to 6-monthly denosumab injections along with calcium and vitamin D, which has been continued. Her RA remains active, and she has recently commenced JAK2 inhibitors. Case report - Discussion Inflammatory arthropathies such as RA predispose to significant morbidity and disability. An earlier age of diagnosis poses a longer inflammatory response in body, with a higher incidence of bone health complications. A treat-to-target strategy in RA aids optimal disease management and reduces fracture risk. Studies have shown the risk of osteoporosis in RA is not just disease dependent but also affected by certain medications. Treatment challenges arise when a patient sustains fracture despite a BMD above osteoporosis risk criteria, leading us to consider other variables. She was further investigated for secondary causes of osteoporosis, including endocrine causes, and was found to be vitamin D insufficient, which was replaced prior to further antiresorptive treatment. Our case also highlights a diagnostic dilemma given that our patient presented with a single swollen joint assumed to be due to active RA. Multiple insufficiency fractures were only identified after MRI was performed. As per EULAR criteria, our patient had difficult to treat RA with a long disease duration. She showed intolerance to a several DMARDs and treatment failure with multiple biologic therapies. She had required local joint injections and repeated short courses of oral steroids. These factors are likely to have played a considerable role in her fracture development. RA is an independent risk factor for fracture in both men and women with disease duration and CS use being important clinical variables. Bisphosphonates are considered vital in fracture risk reduction. The compliance is an important factor for both primary and secondary prevention of fracture. They are associated with decreased bone remodelling and have been well studied for atypical femoral fractures; however, whether there is any link with stress fractures in the feet requires further studies. Long-term use (>5years) hasn’t shown to be beneficial in preventing hip fractures. Case report - Key learning points


2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 1532-1532
Author(s):  
A. P. O'Dea ◽  
M. Thirunavu ◽  
J. Nydegger ◽  
J. R. Klemp ◽  
B. F. Kimler ◽  
...  

1532 Background: Tamoxifen when used in the high estrogen milieu of premenopausal women may reduce bone density. However, the proportion of premenopausal women at increased risk for breast cancer who have low bone density and are likely to take tamoxifen is unknown. Methods: Premenopausal women attending a high-risk clinic were invited to take part in an ongoing prospective study assessing bone mineral density (BMD) loss. Women on bisphosphonates or those previously treated with selective estrogen receptor modulators were excluded. BMD was measured by DEXA, serum 25-hydroxyvitamin D (25OHD) by chemiluminescence, and information on risk factors for osteoporosis and breast cancer was obtained by questionnaire. Results: 106 premenopausal women were entered between April and October 2008. Median age was 42 (range 23–57), median body mass index (BMI) was 25 kg/m2 (range 15–44). All but two were Caucasian. 13% had a prior biopsy with atypical hyperplasia (AH) or in situ carcinoma, 36% had a family history of osteoporosis, 56% took calcium supplements, and 47% took vitamin D supplements. Median sun exposure was 480 minutes per month, the majority with sunscreen. Median serum 25OHD was 34 ng/ml. Five had deficiency (< 20 ng/mL), and 45 women deficiency or insufficiency (< 32 ng/mL). Seven subjects ages 31 to 48 had evidence of low BMD (T-score of less than -1.0 in the spine or hip.) One woman with low BMD by DEXA had a 25OHD level < 32 ng/ml. Women with low BMD had lower BMIs (median of 22 vs. 25 kg/m2, p = 0.020) than women with normal bone density. There was no difference in history of vitamin D and calcium supplement use, and low 25OHD levels did not explain the low T-scores. Information on vitamin D receptor polymorphisms associated with BMD loss is pending. Importantly, 21% of women with a prior biopsy demonstrating AH or in situ carcinoma had evidence of bone density loss compared to 4% of women without such a biopsy (p = 0.048). Conclusions: Premenopausal women with a history of AH or in situ carcinoma are most likely to take tamoxifen for primary prevention and in our ongoing study have a high enough incidence of low bone density to make baseline assessment by DEXA a consideration, particularly for those with predisposing factors such as low BMI and lack of sun exposure. No significant financial relationships to disclose.


Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 1783-1783
Author(s):  
Jennifer L. Kelly ◽  
Jonathan W. Friedberg ◽  
Laura M. Calvi ◽  
Edwin van Wijngaarden ◽  
Susan G. Fisher

Abstract While a large number of exogenous and endogenous factors have been examined, the etiology of most lymphoma subtypes remains largely unknown. However, recent research suggests that sunlight exposure is associated with reduced lymphoma risk. As sunlight is our major source of vitamin D, it has been suggested that increases in serum vitamin D are responsible for this association. Extra-renal activation of vitamin D results in autocrine and paracrine effects including: maintaining regulation of cell cycle proliferation, apoptosis induction, and increased cell differentiation signaling. Animal and human studies investigating the association between vitamin D and other cancers have provided support for a protective effect of vitamin D related to malignancy. We conducted a case-control study in western New York State to test the hypothesis that a history of vitamin D insufficiency increases the risk of lymphoma. Between October 2005 and September 2007, we recruited 140 newly diagnosed and previously untreated lymphoma cases and 139 clinic-based controls. Cases and controls were recruited concurrently to account for seasonal variation in vitamin D, and a serum sample and self-administered survey were collected from each subject. Current serum 25(OH)D levels were measured by radioimmunoassay (Heartland Assays Inc., Ames, IA). We used multiple linear regression to obtain quantitative estimates of past (5–10 years ago) serum vitamin D concentrations based on survey data and measured current vitamin D levels. Subsequently, we evaluated the association between estimated past vitamin D insufficiency (25(OH)D &lt; 30 ng/mL) and lymphoma risk with multiple logistic regression, controlling for the effects of age, gender, race, prior skin cancer diagnosis, known family history of lymphoma or other cancer, alcohol use, and BMI. Additionally, we examined the association between self-reported past sun exposure and lymphoma risk. The case population included 89 males (64%), 124 whites (89%), and median age was 60; the control population included 61 males (44%), 123 whites (88%), and median age was 52. Median time between case diagnosis and study participation was 21 days (5 month maximum). Cases presented predominantly with advanced stage (64% Stage III/IV) diffuse large B cell lymphoma (23%) and follicular lymphoma (32%) subtypes, and 30 (21%) cases had documented B symptoms. While serum vitamin D values ranged from 2.5 to 45.6 ng/mL, we were surprised to find that the majority of the study population (74%) was vitamin D insufficient. Those with past vitamin D insufficiency were found to have a slightly lower lymphoma risk (multivariate adjusted odds ratio (OR) = 0.68; 95% confidence interval (CI) = 0.38 – 1.23), but this result was not statistically significant. Self-reported past sunbathing (OR=0.30, 95% CI: 0.11–0.85) and past outdoor occupation (OR=0.49, 95% CI: 0.25–0.96) were statistically significantly associated with reduced lymphoma risk. This study fails to provide evidence to support an important role of vitamin D insufficiency in lymphoma etiology. However, we confirmed the previously reported decrease in lymphoma risk associated with measures of increased sun exposure, thereby supporting the validity of our study data. Moreover, our findings suggest that vitamin D insufficiency may not explain the observed association between sun and lymphoma. In light of both the high prevalence of vitamin D insufficiency and the known risk of excessive chronic sun exposure, further investigation of the risks of vitamin D insufficiency, as well as alternative pathways for the demonstrated inverse associations between sun exposure and lymphoma risk, is warranted.


Sign in / Sign up

Export Citation Format

Share Document